INTRODUCTION AND OBJECTIVES: Injectable follicle stimulating hormone (FSH) is used to establish or restore fertility in men with hypogonadotropic hypogonadism (HH) and provides ovarian stimulation (OS) in women undergoing both in vitro fertilization (IVF) and oocyte cryopreservation (OCP). Brand FSH (B-FSH) is prohibitively expensive and can be a major roadblock to couples pursuing fertility treatment. Here we provide the first analysis of the clinical efficacy and cost-effectiveness of compounded FSH (C-FSH) in both men and women.
INTRODUCTION AND OBJECTIVES: Injectable follicle stimulating hormone (FSH) is used to establish or restore fertility in men with hypogonadotropic hypogonadism (HH) and provides ovarian stimulation (OS) in women undergoing both in vitro fertilization (IVF) and oocyte cryopreservation (OCP). Brand FSH (B-FSH) is prohibitively expensive and can be a major roadblock to couples pursuing fertility treatment. Here we provide the first analysis of the clinical efficacy and cost-effectiveness of compounded FSH (C-FSH) in both men and women.
METHODS: Retrospective chart review identified all men prescribed C-FSH with azo/severe oligozoospermia (<5 million sperm) and HH refractory to clomiphene citrate. FSH levels, semen analysis, and pregnancy outcomes were noted and median pre/post-treatment levels were analyzed using the Wilcoxon test. All females referred for IVF that used C-FSH for IVF or OCP were included. All C-FSH prescriptions were obtained through the same specialty compounding pharmacy in Houston, TX. Average cost of B-FSH was derived from the top 9 commercial pharmacies listed on www.GoodRx.com and compared to C-FSH to determine the estimated cost of a typical male or female course of therapy.
RESULTS: 16 men were prescribed C-FSH and met inclusion criteria (Table 1) . Median FSH levels showed a significant, 16-fold increase from baseline (p<0.0004). All 13 men with semen analysis data showed improved sperm concentration and total motile count (TMC) with C-FSH therapy. Of 9 men attempting pregnancy, 6 (66.7%) achieved with 8 live births (2 twins). 6 female patients initiated IVF or OCP, resulting in a median retrieval of 14.5 (7-29) mature oocytes, a 72% fertilization rate, 8.5 (5-13) mature blastocysts, 2 transferred embryos and 2 singleton pregnancies. Cost analysis demonstrated significantly lower cost for C-FSH ($0.20) compared to B-FSH ($2.20).
CONCLUSIONS: In this novel analysis, C-FSH therapy resulted in significantly improved serum FSH levels, sperm concentration and TMC in men with HH. It also showed excellent OS of women undergoing IVF and yielded several pregnancies, validating the clinical effectiveness of C-FSH. Compared to B-FSH, C-FSH provides unprecedented cost savings to male and female patients undergoing FSH therapy and may allow some couples to achieve parenthood who otherwise would be prohibited by cost.
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MP52-18 PREDNISONE AFTER VASECTOMY REVERSAL MAY IMPROVE SEMEN PARAMETERS
Graham Machen*, Jay Sandlow, Milwaukee, WI INTRODUCTION AND OBJECTIVES: Although corticosteroids have been used for decades in the treatment of immunologic infertility, data supporting their use following vasectomy reversal (VR) remains sparse. The rationale is that given their anti-inflammatory properties, they may be able to reverse early scarring due to inflammation. We set out to examine the safety and efficacy of corticosteroids in this subset of patients.
METHODS: A chart review was undertaken from Jan 1 2008 to Sep 30 2018 to identify men who had undergone a VR and received prednisone post-op. Prednisone was prescribed to individuals with possible scarring or inflammation, which was suspected based on sub-optimal or decreases in semen parameters. Exclusion criteria included lack of follow up or no semen analysis after steroid administration. A course of prednisone consisted of the following regimen: 2 weeks of 20 mg daily followed by 2 weeks of 10 mg daily. This was repeated at the discretion of the provider. Statistical calculations were done using student's t-test where appropriate.
RESULTS: A total of 89 patients who received post-reversal steroids were identified out of a total of 368 patients (24.1%). The mean patient age was 40.1 (SD 6.48), partner age was 32.45 (SD 4.46) and obstructive interval after vasectomy was 7.80 years (SD 5.88) . See table 1 for summary of results. The overall patency rate was 85.7%. Semen analyses were obtained a mean of 1.16 months (SD 1.79) after completing prednisone. A subanalysis of 24 men with azoospermia at the time of steroid initiation showed an improvement in 11(45.8%) and 8(33.3%) men for concentration and TMC. One patient experienced mild adrenal insufficiency based on symptoms; he was given an additional burst and taper and his symptoms resolved. Otherwise there were no side effects reported.
CONCLUSIONS: A total of 89 patients who received postreversal steroids were identified out of a total of 368 patients (24.1%). The mean patient age was 40.1 (SD 6.48), partner age was 32.45 (SD 4.46) and obstructive interval after vasectomy was 7.80 years (SD 5.88 Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
